Intrigued by a report showing to improve the phenotype of Huntington disease (HD) by a HDAC4 genetic suppression in the R6/2 mouse model [26] Stott et al. took interest in targeting class IIa HDACs [27]. Here, HDAC4 is linked to juvenile Huntington disease.